1Rajan A, Gutierrez M, Giaccone G. Newer opportunities in sys- temic therapy of lung cancer[ J]. Ann Oncol, 2008,19:31-37.
2Rudd RM, Gower NH, Spiro SG, et al. Gemcitabine plus car- boplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non small cell lung cancer. Aphase Ill ran- domized study of the London Cancer Group[J]. J Clin Oncol, 2005, 23 : 142-153.
3Martoni A, Marino A, Sperandi F, et al. Muhicentre random- ized phase IU study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer[ J]. Eur J Cancer, 2005, 41:81-92.
4Folkman J. What is the evidence that tumors are angiogenesis dependent? [J]. J National Cancer Institute,1990, 82: 4-6.
5Jenab-Wolcott J. Giantonio BJ. Bevacizumab: current indica- tions and future development for management of solid tumors [J]. Expert opinion biological therapy, 2009, 9: 507-517.
6Jain RK. Normalization of tumor vasculature: an emerging con-cept in antiangiogenic therapy[J]. Science, 2005, 307: 58-62.
7Sakurai H, Asamura H, Goya H, et al. Survival differences by gender for resected non-small cell lung cancer a retrospective a- nalysis of 12,509 cases in a japanese lung cancer registry study [Jl. J Thorac Oncol, 2010, 5:1594-1601.
8Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin a- lone or with bevacizumab for Non-Small-Cell Lung Cancer[ J ]. N Engl J Med, 2006, 355:2542-2550.
9Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cis- platin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small cell lung cancer: A- VAil[J]. J Clin Oncol, 2009, 27:1227-1234.
10Barlesi F, DvomichenkoV, Kim JH, et al. AVAPERL ( MO22089 ) : final efficacy outcomes for patients with advanced non-squamous non-small cell lung cancer randomised to contin- uation maintenance with bevacizumab or bevacizumab + peme- trexed after first-line bevaeizumal3-eisplatin-pemetrexed treat- ment. Presented at 2011 ECCOESMO European Multidiscipli- nary Cancer Congress[J]. Eur J Cancer, 2011,47:34LBA.
